Amarin slips 3% on bearish coverage [Seeking Alpha]
Acasti Pharma, Inc. - Class A (ACST)
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: Seeking Alpha
Amarin slips 3% on bearish coverage Oppenheimer initiates Amarin (NASDAQ: AMRN whopping 70% downside Among the negative items: The 12-month stream of late-stage competitor data beginning next month will increasingly weigh on Vascepa (h/t Notable Calls Marc Lehman Shares are down 3.9% Apparently included in the Oppenheimer report is a positive read-through for Acasti Pharma (NASDAQ: ACST up 4.9%
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Acasti Pharma Inc. (NASDAQ: ACST) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial [Yahoo! Finance]Yahoo! Finance
- Acasti Announces Poster Detailing its GTX-104 STRIVE-ON TrialGlobeNewswire
ACST
Earnings
- 2/12/24 - Beat
ACST
Sec Filings
- 4/9/24 - Form SC
- 4/1/24 - Form 8-K
- 2/13/24 - Form SC
- ACST's page on the SEC website